---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007004"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:20:40.982542+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics Q3 2025 net loss $14.3M; cash $220M; tovecimig OS/PFS data late Q1 2026

## Summary
- Net loss Q3 2025 $14.3M ($0.08/share) vs $10.5M ($0.08) Q3 2024; nine-month loss $50.8M ($0.34).
- Cash and marketable securities $220M as of Sep 30, 2025, up from $127M Dec 2024; cash runway through 2028.
- Tovecimig: OS and PFS data from Phase 2/3 COMPANION-002 in BTC expected late Q1 2026.
- CTX-8371 Phase 1 fully enrolled, no DLTs; cohort expansions in NSCLC and TNBC start Q4 2025; data H1 2026.
- CTX-10726 IND filing on track for Q4 2025; initial Phase 1 data expected H2 2026.

## SEC filing metadata
- accession: 0001171843-25-007004
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184325007004/0001171843-25-007004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184325007004/f8k_103125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007004
- JSON: https://secwatch.observer/filing/0001171843-25-007004.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.